Bhadri: The biggest concern is whats driving the cheaper price point, because in this category, cost reduction almost always means compromise somewhere in the chain
Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS
Here is a realistic breakdown of outcomes: Best responders (~20% of patients): Weight loss of 46 kg over the first year
As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously , the purity demands are higher than single-target peptides
Gastrointestinal effects represent the most common area of potential overlap
However, studies support GLP-1RA to be cost effective in comparison to insulin therapy as per the healthcare models in high income countries while the parameter for comparison between the two include the increased risk of hypoglycaemia and all-cause mortality alongside emergency room visits and hospitalization